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We thank Dr. Zhang for his comments, which are a
welcome addition to the debate about Infection
Control in lung function laboratories. The purpose
of writing the review was to stimulate and to focus
discussion on this controversial topic. As we stated
in the article, there is a spectrum of approaches to
infection control ranging from minimal, selective
precautions through to stringent, universally ap-
plied precautions. While we described what we
believe to be to a practical, cost-effective and
commonsense approach based on the evidence
available, we accept that this may be controver-
sial, as the evidence base is poor.
The difference in approach taken by Dr. Zhang
and ourselves is presumably based on different
assessments of the probability of transmission of
infection during lung function tests. Dr. Zhang
considers the risks of cross-infection to be much
higher than the evidence currently available
suggests, i.e. many infections are associated with
lung function testing procedures but the link is not
being reported). This may be the case and we
would wholeheartedly support the need for much
more work to be done regarding the potential for
cross-infection in the lung function laboratory.
In considering the approach proposed in our
review, we have not only looked at the evidence
available, but also tried to be realistic in the
context of wider infection control risks. We need to
undertake a risk assessment and using best infor-
mation, commonsense and sound judgement make
an informed decision. This will necessitate imple-
menting improved infection control practices at
any critical point where the risk of infection is
appreciably elevated above that associated with
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about this and must regularly re-evaluate the risks
and revise protocols where appropriate. Indeed we
have to some extent changed our recommendations
over the years, as noted by Dr. Zhang.
To date the best evidence based guidance for ‘‘At
Risk’’ patients comes from the excellent data on
patients with cystic fibrosis. The evidence here is
clear, guidelines have been published and we
support such guidelines both to protect the
patients with cystic fibrosis and non-CF patients
using the same equipment. In these circumstances,
we agree that the use of high quality barrier filters
is appropriate.
Finally, we hope that much more questioning and
evaluation of the risks will occur in the future, and
that this may stimulate practitioners to undertake
funded research in this area. We must remain
vigilant about new risks, review old risks and based
on sound evidence make up to date consensus
guidelines available to all practitioners.A.H. Kendrick
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